Double-digit growth lifts Dexcom (NASDAQ: DXCM) margins and profit
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Dexcom reported strong fourth quarter and full-year 2025 results, with revenue reaching $1.260 billion in Q4, up 13% year over year, and $4.662 billion for 2025, up 16%.
Profitability improved meaningfully. Q4 GAAP operating income rose to $323.0 million (25.6% margin), while full-year GAAP operating income reached $911.8 million (19.6% margin). GAAP net income for 2025 increased to $836.3 million, or $2.09 per diluted share.
The company highlighted the U.S. launch of its Dexcom G7 15 Day system, FDA clearance for Dexcom Smart Basal, and expanded reimbursement in Québec. Dexcom ended 2025 with $2.00 billion in cash, cash equivalents and marketable securities and reiterated 2026 guidance, including revenue of $5.16–$5.25 billion and non-GAAP operating margin of approximately 22–23%.
Positive
- Strong revenue growth: 2025 revenue rose 16% year-over-year to $4.662 billion, with Q4 revenue up 13% to $1.260 billion.
- Significant margin expansion: 2025 GAAP operating income reached $911.8 million with a 19.6% margin, while non-GAAP operating margin improved to 20.8%.
- Earnings acceleration: 2025 GAAP net income increased to $836.3 million, or $2.09 diluted EPS, compared with $1.42 in 2024.
- Healthy balance sheet: Dexcom ended 2025 with $2.00 billion in cash, cash equivalents and marketable securities, and its revolving credit facility remained undrawn.
- Supportive 2026 outlook: The company reiterated 2026 revenue guidance of $5.16–$5.25 billion (approximately 11–13% growth) and targeted non-GAAP operating margin of about 22–23%.
Negative
- None.
Insights
Dexcom delivers double-digit growth, margin expansion, and confident 2026 guidance.
Dexcom showed robust top-line momentum in 2025, with revenue rising to
Profitability improved sharply. GAAP operating income increased to
The balance sheet remains strong, with
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 12, 2026
(Exact Name of the Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
(858 ) 200-0200
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||||||||||||||
Emerging growth company | ||||||||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | |||||||||||||
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On February 12, 2026, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
| Number | Description | |||||||
| 99.1 | Press release dated February 12, 2026 | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DEXCOM, INC. | ||||||||
| By: | /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | |||||||
Date: | February 12, 2026 | |||||||
Exhibit 99.1
Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results
SAN DIEGO - (BUSINESS WIRE-February 12, 2026) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025.
Fourth Quarter 2025 Financial Highlights:
•Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis.
•U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis.
•GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth quarter of 2024.
Full Year 2025 Financial Highlights:
•Full year revenue grew 16% versus the prior year to $4.662 billion on a reported basis and 15% on an organic2 basis.
•U.S. revenue growth of 15% and international revenue growth of 16% on a reported basis. International revenue growth was 15% on an organic2 basis.
•GAAP operating income of $911.8 million or 19.6% of revenue, an increase of 470 basis points compared to 2024. Non-GAAP operating income* of $969.3 million or 20.8% of revenue, an increase of 200 basis points over the prior year.
Fourth Quarter 2025 Strategic Highlights:
•Launched Dexcom G7 15 Day CGM system in the United States
•Received FDA clearance for Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer
•Expanded access to Dexcom CGM in Québec under the Régie de l'assurance maladie du Québec (RAMQ), bringing coverage to eligible adults with type 2 diabetes
“2025 was another great year for Dexcom as we significantly expanded access to Dexcom CGM and launched our Dexcom G7 15 Day System,” said Jake Leach, Dexcom’s president and CEO. “We look forward to building on this momentum in 2026 as we work to deliver improved health outcomes for many more people globally."
2026 Annual Guidance
Dexcom is reiterating fiscal year 2026 guidance for Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and establishing Adjusted EBITDA Margin guidance at the following levels:
•Revenue of $5.16 - $5.25 billion (approximately 11-13% growth)
•Non-GAAP Gross Profit Margin of approximately 63-64%
•Non-GAAP Operating Margin of approximately 22-23%
•Adjusted EBITDA Margin of approximately 30-31%
1 Fourth quarter 2025 organic revenue was $1.250 billion and excludes $9.4 million of foreign exchange impact.
2 Full year 2025 organic revenue is $4.645 billion and excludes $17.1 million of foreign exchange impact.
Fourth Quarter 2025 Financial Results
Revenue: In the fourth quarter of 2025, worldwide revenue grew 13% to $1.260 billion on a reported basis, up from $1.114 billion in the fourth quarter of 2024.
Gross Profit: GAAP gross profit totaled $792.7 million or 62.9% of revenue for the fourth quarter of 2025, compared to $655.8 million or 58.9% of revenue in the fourth quarter of 2024.
Non-GAAP gross profit* totaled $799.8 million or 63.5% of reported revenue for the fourth quarter of 2025, compared to $661.2 million or 59.4% of reported revenue in the fourth quarter of 2024.
Operating Income: GAAP operating income for the fourth quarter of 2025 was $323.0 million or 25.6% of revenue, compared to GAAP operating income of $188.9 million or 17.0% of revenue for the fourth quarter of 2024.
Non-GAAP operating income* for the fourth quarter of 2025 was $331.5 million or 26.3% of reported revenue, compared to non-GAAP operating income of $209.5 million or 18.8% of reported revenue for the fourth quarter of 2024.
Net Income and Diluted Net Income Per Share: GAAP net income was $267.3 million, or $0.68 per diluted share, for the fourth quarter of 2025, compared to GAAP net income of $151.7 million, or $0.38 per diluted share, for the fourth quarter of 2024.
Non-GAAP net income* was $265.1 million, or $0.68 per diluted share, for the fourth quarter of 2025, compared to non-GAAP net income of $177.8 million, or $0.45 per diluted share, for the fourth quarter of 2024. The fourth quarter 2025 non-GAAP net income excludes $7.9 million of amortization of intangible assets, $0.6 million of business transition and other significant items, and $10.7 million of tax adjustments.
Cash and Liquidity: As of December 31, 2025, Dexcom held $2.00 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.
* See Table D below for a reconciliation of these GAAP and non-GAAP financial measures.
Conference Call
Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. To listen to the conference call, please dial (888) 414-4585 (U.S./Canada) or (646) 960-0331 (International) and use the confirmation ID “9430114” approximately five minutes prior to the start time.
Statement Regarding Use of Non-GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), please see the section titled “About Non-GAAP Financial Measures” below as well as the related Table D. We have not reconciled our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin estimates for fiscal year 2025 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, reconciliations of our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates are not available without unreasonable effort.
About DexCom, Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
Category: IR
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s future operating results and financial position, including estimated Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin for fiscal year 2026, and expected growth rates as compared to the year ended December 31, 2025; future expenses and investments; and potential business plans and opportunities. All forward-looking statements included in this press release are made as of the date of this press release, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and are therefore subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.
INVESTOR RELATIONS CONTACT:
Sean Christensen
Vice President - Finance and Investor Relations
investor-relations@dexcom.com
(858) 203-6657
MEDIA CONTACT:
James McIntosh
(619) 884-2118
DexCom, Inc.
Table A
Consolidated Balance Sheets
(In millions, except par value data)
(Unaudited)
| December 31, 2025 | December 31, 2024 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 917.7 | $ | 606.1 | |||||||
| Short-term marketable securities | 1,081.0 | 1,973.3 | |||||||||
| Accounts receivable, net | 1,216.1 | 1,005.7 | |||||||||
| Inventory | 629.1 | 542.6 | |||||||||
| Prepaid and other current assets | 189.4 | 173.7 | |||||||||
| Total current assets | 4,033.3 | 4,301.4 | |||||||||
| Property and equipment, net | 1,559.9 | 1,339.9 | |||||||||
| Operating lease right-of-use assets | 77.4 | 62.8 | |||||||||
| Goodwill | 24.2 | 22.8 | |||||||||
| Intangibles, net | 70.8 | 103.4 | |||||||||
| Deferred tax assets | 295.6 | 481.2 | |||||||||
| Other assets | 278.7 | 173.0 | |||||||||
| Total assets | $ | 6,339.9 | $ | 6,484.5 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued liabilities | $ | 1,944.0 | $ | 1,585.1 | |||||||
| Accrued payroll and related expenses | 169.2 | 112.0 | |||||||||
| Current portion of long-term senior convertible notes | — | 1,204.4 | |||||||||
| Short-term operating lease liabilities | 21.6 | 22.5 | |||||||||
Other current liabilities | 7.7 | 8.0 | |||||||||
| Total current liabilities | 2,142.5 | 2,932.0 | |||||||||
| Long-term senior convertible notes | 1,240.9 | 1,237.0 | |||||||||
| Long-term operating lease liabilities | 73.4 | 65.0 | |||||||||
| Other long-term liabilities | 137.1 | 147.9 | |||||||||
| Total liabilities | 3,593.9 | 4,381.9 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — | |||||||||
Common stock, $0.001 par value, 800.0 million shares authorized; 410.7 million and 384.8 million shares issued and outstanding, respectively, at December 31, 2025; and 408.9 million and 390.7 million shares issued and outstanding, respectively, at December 31, 2024 | 0.4 | 0.4 | |||||||||
| Additional paid-in capital | 2,281.5 | 2,093.8 | |||||||||
Accumulated other comprehensive income (loss) | 115.0 | (8.0) | |||||||||
| Retained earnings | 2,433.9 | 1,597.6 | |||||||||
Treasury stock, at cost; 25.9 million shares at December 31, 2025 and 18.2 million shares at December 31, 2024 | (2,084.8) | (1,581.2) | |||||||||
| Total stockholders’ equity | 2,746.0 | 2,102.6 | |||||||||
| Total liabilities and stockholders’ equity | $ | 6,339.9 | $ | 6,484.5 | |||||||
DexCom, Inc.
Table B
Consolidated Statements of Operations
(In millions, except per share data)
(Unaudited)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Revenue | $ | 1,259.6 | $ | 1,113.5 | $ | 4,662.0 | $ | 4,033.0 | |||||||||||||||
| Cost of sales | 466.9 | 457.7 | 1,860.1 | 1,594.8 | |||||||||||||||||||
| Gross profit | 792.7 | 655.8 | 2,801.9 | 2,438.2 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 148.2 | 139.5 | 599.1 | 552.4 | |||||||||||||||||||
| Selling, general and administrative | 321.5 | 327.4 | 1,291.0 | 1,285.8 | |||||||||||||||||||
| Total operating expenses | 469.7 | 466.9 | 1,890.1 | 1,838.2 | |||||||||||||||||||
| Operating income | 323.0 | 188.9 | 911.8 | 600.0 | |||||||||||||||||||
| Other income, net | 17.7 | 22.4 | 176.6 | 109.0 | |||||||||||||||||||
| Income before income taxes | 340.7 | 211.3 | 1,088.4 | 709.0 | |||||||||||||||||||
| Income tax expense | 73.4 | 59.6 | 252.1 | 132.8 | |||||||||||||||||||
| Net income | $ | 267.3 | $ | 151.7 | $ | 836.3 | $ | 576.2 | |||||||||||||||
| Basic net income per share | $ | 0.69 | $ | 0.39 | $ | 2.14 | $ | 1.46 | |||||||||||||||
| Shares used to compute basic net income per share | 386.7 | 390.6 | 390.2 | 393.6 | |||||||||||||||||||
| Diluted net income per share | $ | 0.68 | $ | 0.38 | $ | 2.09 | $ | 1.42 | |||||||||||||||
| Shares used to compute diluted net income per share | 398.9 | 406.7 | 405.5 | 412.7 | |||||||||||||||||||
DexCom, Inc.
Table C
Revenue by Customer Sales Channel and Geographic Region
(Dollars in millions)
(Unaudited)
| Three Months Ended December 31, | |||||||||||||||||||||||||||||||||||
| 2025 | 2024 | ||||||||||||||||||||||||||||||||||
| (In millions) | United States | International | Total | United States | International | Total | |||||||||||||||||||||||||||||
| Distributor | $ | 857.0 | $ | 218.2 | $ | 1,075.2 | $ | 773.2 | $ | 174.7 | $ | 947.9 | |||||||||||||||||||||||
| Direct | 34.5 | 149.9 | 184.4 | 29.6 | 136.0 | 165.6 | |||||||||||||||||||||||||||||
| Total revenue | $ | 891.5 | $ | 368.1 | $ | 1,259.6 | $ | 802.8 | $ | 310.7 | $ | 1,113.5 | |||||||||||||||||||||||
| Twelve Months Ended December 31, | |||||||||||||||||||||||||||||||||||
| 2025 | 2024 | ||||||||||||||||||||||||||||||||||
| (In millions) | United States | International | Total | United States | International | Total | |||||||||||||||||||||||||||||
| Distributor | $ | 3,195.7 | $ | 763.3 | $ | 3,959.0 | $ | 2,824.4 | $ | 605.7 | $ | 3,430.1 | |||||||||||||||||||||||
| Direct | 139.2 | 563.8 | 703.0 | 65.4 | 537.5 | 602.9 | |||||||||||||||||||||||||||||
| Total revenue | $ | 3,334.9 | $ | 1,327.1 | $ | 4,662.0 | $ | 2,889.8 | $ | 1,143.2 | $ | 4,033.0 | |||||||||||||||||||||||
DexCom, Inc.
Table D
Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures
(In millions, except per share data)
(Unaudited)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| GAAP gross profit | $ | 792.7 | $ | 655.8 | $ | 2,801.9 | $ | 2,438.2 | |||||||||||||||
Amortization of intangible assets (1) | 7.2 | 7.2 | 28.6 | 28.6 | |||||||||||||||||||
Business transition and other significant items (2) | (0.1) | (1.8) | 2.7 | 30.5 | |||||||||||||||||||
Credits related to COVID-19 (3) | — | — | — | (3.0) | |||||||||||||||||||
| Non-GAAP gross profit | $ | 799.8 | $ | 661.2 | $ | 2,833.2 | $ | 2,494.3 | |||||||||||||||
| GAAP operating income | $ | 323.0 | $ | 188.9 | $ | 911.8 | $ | 600.0 | |||||||||||||||
Amortization of intangible assets (1) | 7.9 | 8.0 | 31.7 | 35.1 | |||||||||||||||||||
Business transition and other significant items (2) | 0.6 | (0.9) | 25.4 | 38.5 | |||||||||||||||||||
Credits related to COVID-19 (3) | — | — | — | (3.2) | |||||||||||||||||||
Intellectual property litigation costs (4) | — | 13.5 | 0.4 | 86.7 | |||||||||||||||||||
| Non-GAAP operating income | $ | 331.5 | $ | 209.5 | $ | 969.3 | $ | 757.1 | |||||||||||||||
| GAAP net income | $ | 267.3 | $ | 151.7 | $ | 836.3 | $ | 576.2 | |||||||||||||||
Business transition and other significant items (2) | 0.6 | (1.0) | 20.9 | 38.2 | |||||||||||||||||||
Credits related to COVID-19 (3) | — | — | — | (3.2) | |||||||||||||||||||
| Depreciation and amortization | 65.2 | 57.8 | 251.8 | 217.7 | |||||||||||||||||||
Intellectual property litigation costs (4) | — | 13.5 | 0.4 | 86.7 | |||||||||||||||||||
(Income) loss from equity investments | — | — | (78.1) | 1.4 | |||||||||||||||||||
| Share-based compensation | 35.0 | 43.3 | 159.6 | 170.4 | |||||||||||||||||||
| Interest expense and interest income | (19.3) | (24.8) | (94.4) | (115.2) | |||||||||||||||||||
| Income tax expense | 73.4 | 59.6 | 252.1 | 132.8 | |||||||||||||||||||
| Adjusted EBITDA | $ | 422.2 | $ | 300.1 | $ | 1,348.6 | $ | 1,105.0 | |||||||||||||||
| GAAP net income | $ | 267.3 | $ | 151.7 | $ | 836.3 | $ | 576.2 | |||||||||||||||
Amortization of intangible assets (1) | 7.9 | 8.0 | 31.7 | 35.1 | |||||||||||||||||||
Business transition and other significant items (2) | 0.6 | (0.9) | 25.4 | 38.5 | |||||||||||||||||||
Credits related to COVID-19 (3) | — | — | — | (3.2) | |||||||||||||||||||
Intellectual property litigation costs (4) | — | 13.5 | 0.4 | 86.7 | |||||||||||||||||||
(Income) loss from equity investments | — | — | (78.1) | 1.4 | |||||||||||||||||||
Adjustments related to taxes (5) | (10.7) | 5.5 | 12.4 | (74.5) | |||||||||||||||||||
| Non-GAAP net income | $ | 265.1 | $ | 177.8 | $ | 828.1 | $ | 660.2 | |||||||||||||||
DexCom, Inc.
Table D (Continued)
Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures
(In millions, except per share data)
(Unaudited)
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| GAAP net income | $ | 267.3 | $ | 151.7 | $ | 836.3 | $ | 576.2 | |||||||||||||||
| Interest expense on senior convertible notes, net of tax | 2.4 | 2.8 | 11.0 | 11.5 | |||||||||||||||||||
GAAP net income used for diluted EPS, if-converted (6) | $ | 269.7 | $ | 154.5 | $ | 847.3 | $ | 587.7 | |||||||||||||||
| Non-GAAP net income | $ | 265.1 | $ | 177.8 | $ | 828.1 | $ | 660.2 | |||||||||||||||
| Interest expense on senior convertible notes, net of tax | 0.8 | 1.2 | 4.5 | 4.9 | |||||||||||||||||||
Non-GAAP net income used for diluted EPS, if-converted (6) | $ | 265.9 | $ | 179.0 | $ | 832.6 | $ | 665.1 | |||||||||||||||
GAAP diluted net income per share (6) | $ | 0.68 | $ | 0.38 | $ | 2.09 | $ | 1.42 | |||||||||||||||
Amortization of intangible assets (1) | 0.02 | 0.02 | 0.08 | 0.09 | |||||||||||||||||||
Business transition and other significant items (2) | — | — | 0.06 | 0.10 | |||||||||||||||||||
Credits related to COVID-19 (3) | — | — | — | (0.01) | |||||||||||||||||||
Intellectual property litigation costs (4) | — | 0.03 | — | 0.21 | |||||||||||||||||||
(Income) loss from equity investments | — | — | (0.20) | — | |||||||||||||||||||
Adjustments related to taxes (5) | (0.03) | 0.01 | 0.03 | (0.18) | |||||||||||||||||||
Impact of adjustment to GAAP diluted shares (7) | 0.01 | — | 0.01 | — | |||||||||||||||||||
Non-GAAP diluted net income per share (6) (8) | $ | 0.68 | $ | 0.45 | $ | 2.09 | $ | 1.64 | |||||||||||||||
| GAAP diluted weighted-average shares outstanding | 398.9 | 406.7 | 405.5 | 412.7 | |||||||||||||||||||
| Non-GAAP diluted weighted-average shares outstanding | 391.2 | 399.0 | 397.8 | 405.0 | |||||||||||||||||||
| Reconciliation of non-GAAP diluted weighted-average shares outstanding: | |||||||||||||||||||||||
| GAAP diluted weighted-average shares outstanding | 398.9 | 406.7 | 405.5 | 412.7 | |||||||||||||||||||
Adjustment for dilutive impact of senior convertible notes due 2028 (9) | (7.7) | (7.7) | (7.7) | (7.7) | |||||||||||||||||||
| Non-GAAP diluted weighted-average shares outstanding | 391.2 | 399.0 | 397.8 | 405.0 | |||||||||||||||||||
(1) Represents amortization of acquired intangible assets.
(2) For the three months ended December 31, 2025, business transition and other significant items are primarily related to rent for vacated office space in San Diego, California. For the twelve months ended December 31, 2025, business transition and other significant items are primarily related to workforce reduction costs associated with organizational realignment and rent for vacated office space in San Diego, California. For the three months ended December 31, 2024, business transition and other significant items are primarily related to adjustments to the non-cash inventory build charge and rent for vacated office space in San Diego, California. For the twelve months ended December 31, 2024, business transition and other significant items are primarily related to a $22.7 million non-cash inventory build charge, the divestiture of our non-diabetes distribution business, workforce reduction costs, and rent for vacated office space in San Diego, California.
(3) Represents a credit received related to employment of personnel during the COVID-19 pandemic.
(4) We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled “Legal Proceedings” in Dexcom’s Annual Report on Form 10-K for the year ended December 31, 2024.
(5) For the three and twelve months ended December 31, 2025, tax adjustments are primarily related to the tax effect of non-GAAP adjustments and shortfalls from share-based compensation for employees. For the three months ended December 31, 2024, tax adjustments are primarily related to the tax effect of non-GAAP adjustments. For the twelve months ended December 31, 2024, tax adjustments are primarily related to the tax effect of the Verily milestone payment, non-GAAP adjustments, and excess tax benefits from share-based compensation for employees.
(6) When our senior convertible notes are dilutive on a GAAP or non-GAAP basis, net income used for calculating GAAP and non-GAAP diluted net income per share includes an interest expense add back, net of tax, under the if-converted method. In loss periods, basic and diluted net loss per share are the same since the effect of potential common shares is anti-dilutive and therefore excluded.
(7) The adjustments are for the transition from GAAP diluted net income per share to non-GAAP diluted net income per share due to our senior convertible notes.
(8) The sum of the non-GAAP per share components may not equal the totals due to rounding.
(9) We adjust for the dilutive effect of our senior convertible notes when the effect is not the same on a GAAP and non-GAAP basis for a given period.
ABOUT NON-GAAP FINANCIAL MEASURES
The accompanying press release dated February 12, 2026 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, non-GAAP diluted net income per share, and non-GAAP diluted weighted average shares outstanding, as well as Adjusted EBITDA.
We report non-GAAP financial measures in addition to, and not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision making and period-to-period comparisons. We believe that these non-GAAP financial measures provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by senior management in our financial and operational decision making. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. While we compute non-GAAP financial measures using a consistent method from quarter to quarter and year to year, we may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.
These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.
We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.
Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude the following items from organic revenue:
•The effect of non-CGM revenue acquired or divested in the trailing twelve months; and
•The effect of foreign currency fluctuations
Management believes that the presentation of operating results that exclude these items provides useful supplemental information to investors and facilitates the analysis of our core operating results and comparison of operating results across reporting periods. Management believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing our past and future operating performance.
Table D reconciles the non-GAAP financial measures included in this press release to the most directly comparable financial measures prepared in accordance with GAAP.
Our policy is to exclude the following items from non-GAAP financial measures for non-GAAP gross profit, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted net income per share:
•Amortization of acquired intangible assets;
•Business transition and related costs associated with acquisition and divestiture, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third-party merger and acquisition costs, and other non-recurring significant items;
•Credits related to the employment of personnel during the COVID-19 pandemic;
•Income or loss from equity investments, which includes realized and unrealized gains or losses from marketable and non-marketable equity securities. These amounts may reflect changes in value due to observable price changes or impairments;
•Third-party intellectual property litigation costs in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc.;
•Litigation settlement costs;
•Gain or loss on extinguishment of debt; and
•Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items
Adjusted EBITDA excludes non-cash operating charges for share-based compensation (including equity-related charges associated with severance, restructuring, or other business transition activities), depreciation and amortization as well as non-operating items such as interest income, interest expense, gain or loss on extinguishment of debt, income or loss from equity investments, and income tax expense or benefit. For the reasons explained above, Adjusted EBITDA also excludes business transition and other significant items, COVID-19 credits, litigation settlement costs, and intellectual property litigation costs.
FAQ
How did Dexcom (DXCM) perform financially in the fourth quarter of 2025?
Dexcom delivered strong Q4 2025 results, with revenue rising 13% year over year to $1.260 billion. GAAP operating income increased to $323.0 million, a 25.6% margin, and GAAP net income reached $267.3 million, or $0.68 per diluted share.
What were Dexcom (DXCM) full-year 2025 revenue and profit figures?
For 2025, Dexcom reported revenue of $4.662 billion, up 16% versus 2024. GAAP operating income was $911.8 million, a 19.6% margin, and GAAP net income totaled $836.3 million, or $2.09 per diluted share, reflecting strong earnings growth.
What guidance did Dexcom (DXCM) provide for its 2026 financial performance?
Dexcom reiterated 2026 revenue guidance of $5.16–$5.25 billion, representing approximately 11–13% growth. It also guided to a non-GAAP gross profit margin of about 63–64%, non-GAAP operating margin of roughly 22–23%, and Adjusted EBITDA margin near 30–31%.
How strong is Dexcom (DXCM)’s balance sheet at the end of 2025?
As of December 31, 2025, Dexcom held $2.00 billion in cash, cash equivalents and marketable securities. Its revolving credit facility remained undrawn, providing additional liquidity and financial flexibility to fund capacity expansion and pursue new market opportunities.
What strategic product and regulatory milestones did Dexcom (DXCM) achieve in 2025?
Key 2025 milestones included the U.S. launch of the Dexcom G7 15 Day system, FDA clearance for Dexcom Smart Basal basal insulin dosing optimizer, and expanded reimbursement access in Québec under RAMQ for eligible adults with type 2 diabetes.
How did Dexcom (DXCM)’s non-GAAP profitability metrics trend in 2025?
Non-GAAP operating income rose to $969.3 million in 2025, a 20.8% operating margin, up from 2024. Adjusted EBITDA reached $1,348.6 million. These improvements reflect higher non-GAAP gross profit of $2,833.2 million and disciplined operating expense management.
Filing Exhibits & Attachments
4 documents
Dexcom Inc
NASDAQ:DXCM
DXCM Rankings
DXCM Latest News
DXCM Latest SEC Filings
Feb 12, 2026
[10-K] DEXCOM INC Files Annual Report
Feb 12, 2026
[144] DEXCOM INC SEC Filing
Feb 2, 2026
[Form 4] DEXCOM INC Insider Trading Activity
Feb 2, 2026
[Form 4] DEXCOM INC Insider Trading Activity
Feb 2, 2026
[Form 4] DEXCOM INC Insider Trading Activity
DXCM Stock Data
26.58B
388.26M
0.42%
97.51%
2.83%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
SAN DIEGO